Chicago Partners Investment Group LLC Buys 1,224 Shares of Medtronic PLC $MDT

Chicago Partners Investment Group LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 17.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 8,194 shares of the medical technology company’s stock after acquiring an additional 1,224 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Medtronic were worth $754,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. GAMMA Investing LLC lifted its stake in Medtronic by 41.1% in the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock valued at $1,427,000 after acquiring an additional 4,626 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Medtronic by 16.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 176,438 shares of the medical technology company’s stock worth $15,855,000 after acquiring an additional 24,777 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in shares of Medtronic by 58.7% during the 1st quarter. JFS Wealth Advisors LLC now owns 3,948 shares of the medical technology company’s stock worth $355,000 after acquiring an additional 1,460 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its holdings in shares of Medtronic by 5.1% in the first quarter. Asset Management One Co. Ltd. now owns 565,134 shares of the medical technology company’s stock valued at $50,783,000 after purchasing an additional 27,232 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.1%

Medtronic stock opened at $95.84 on Wednesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The company’s 50-day moving average is $94.20 and its 200-day moving average is $89.13. The firm has a market capitalization of $122.93 billion, a PE ratio of 26.40, a P/E/G ratio of 2.53 and a beta of 0.78. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $99.37.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. During the same period in the previous year, the company posted $1.23 EPS. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were paid a $0.71 dividend. The ex-dividend date was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is 78.24%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MDT. Citigroup increased their target price on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Mizuho increased their price objective on shares of Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. William Blair upgraded Medtronic to a “hold” rating in a report on Friday, July 11th. Finally, Evercore ISI raised their price target on Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.82.

Insider Activity

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William R. Jellison purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. 0.26% of the stock is owned by corporate insiders.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.